drugset / Trial / NCT03117517

Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome

NCT03117517

Phase 0 Completed 106 enrolled Khyber Medical University Peshawar
RandomizedParallel-groupDouble-blindTreatment

Summary

Objective: 1. To investigate the changes in the levels of interleukin-6 and interleukin-8 after 3 months treatment with metformin alone and combination of metformin and pioglitazone in patients with polycystic ovarian syndrome (PCOS). 2. To evaluate insulin resistance in all the groups at baseline and after 3 months of treatment. Design: Two-Arm Randomized Clinical trial. Setting: Out-Patient Department (OPD) of Mardan Medical Complex, Khyber Medical University. Patient(s): One hundred and two patients with PCOS. Intervention(s): 51 women will receive metformin according to the body weight with maximum dose of 1000 mg (BD) daily. Remaining 51 will receive metformin and pioglitazone combination according to the body weight with maximum dose of 1000 mg and 30 mg (BD) daily. Main outcomes measure(s): Serum concentrations of fasting blood glucose, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), follicle stimulating hormone (FSH), luteinizing hormone (LH), interleukin-6 (IL-6) and i-nterleukin-8 (IL-8).

Timeline

Start
2017-03-20
Primary completion
2017-08-29
Completion
2018-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg Oral
Comparator Pioglitazone Small molecule 30 mg Oral